Compare Stocks: ETON, EWTX, INDV, and DFTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DFTX Definium Therapeutics	$42.32 +1.3%	$36.58	$8.70 ▼ $49.20	$4.17B	2.23	1.86 million shs	1.86 million shs
ETON Eton Pharmaceuticals	$45.83 +1.5%	$36.52	$13.98 ▼ $50.18	$1.24B	0.86	545,631 shs	341,828 shs
EWTX Edgewise Therapeutics	$44.71 +16.5%	$38.82	$12.30 ▼ $48.40	$4.13B	0.3	1.02 million shs	4.18 million shs
INDV Indivior	$36.50 -2.3%	$39.15	$21.16 ▼ $42.81	$4.56B	0.86	1.77 million shs	7.15 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DFTX Definium Therapeutics	+1.27%	+0.86%	-4.23%	+80.70%	+352.14%
ETON Eton Pharmaceuticals	+1.53%	-1.78%	+22.21%	+52.01%	+218.49%
EWTX Edgewise Therapeutics	+16.49%	+10.81%	+13.02%	+20.87%	+228.51%
INDV Indivior	-2.33%	-10.95%	-8.29%	-10.12%	+72.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DFTX Definium Therapeutics	$42.32 +1.3%	$36.58	$8.70 ▼ $49.20	$4.17B	2.23	1.86 million shs	1.86 million shs
ETON Eton Pharmaceuticals	$45.83 +1.5%	$36.52	$13.98 ▼ $50.18	$1.24B	0.86	545,631 shs	341,828 shs
EWTX Edgewise Therapeutics	$44.71 +16.5%	$38.82	$12.30 ▼ $48.40	$4.13B	0.3	1.02 million shs	4.18 million shs
INDV Indivior	$36.50 -2.3%	$39.15	$21.16 ▼ $42.81	$4.56B	0.86	1.77 million shs	7.15 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DFTX Definium Therapeutics	+1.27%	+0.86%	-4.23%	+80.70%	+352.14%
ETON Eton Pharmaceuticals	+1.53%	-1.78%	+22.21%	+52.01%	+218.49%
EWTX Edgewise Therapeutics	+16.49%	+10.81%	+13.02%	+20.87%	+228.51%
INDV Indivior	-2.33%	-10.95%	-8.29%	-10.12%	+72.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DFTX Definium Therapeutics	3.00	Buy	$54.85	29.60% Upside
ETON Eton Pharmaceuticals	2.50	Moderate Buy	$52.50	14.55% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$48.75	9.04% Upside
INDV Indivior	2.71	Moderate Buy	$45.67	25.11% Upside

Current Analyst Ratings Breakdown

Latest ETON, EWTX, INDV, and DFTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2026	INDV Indivior	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$53.00
7/28/2026	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $62.00
7/27/2026	DFTX Definium Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$68.00
7/27/2026	DFTX Definium Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$68.00
7/24/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
7/24/2026	DFTX Definium Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$48.00 ➝ $73.00
7/20/2026	EWTX Edgewise Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$55.00
7/17/2026	DFTX Definium Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ETON Eton Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	EWTX Edgewise Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	ETON Eton Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	$3.36 per share	N/A
ETON Eton Pharmaceuticals	$79.95M	15.70	$0.01 per share	8,708.91	$0.98 per share	46.77
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
INDV Indivior	$1.24B	3.59	$2.66 per share	13.74	($0.78) per share	-46.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DFTX Definium Therapeutics	-$183.79M	-$2.49	N/A	N/A	N/A	N/A	-100.30%	-69.22%	N/A
ETON Eton Pharmaceuticals	-$4.60M	-$0.07	N/A	23.99	N/A	-1.70%	-5.68%	-1.49%	8/13/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.66	N/A	N/A	N/A	N/A	-32.55%	-31.04%	8/6/2026 (Estimated)
INDV Indivior	$210M	$1.95	18.72	8.55	N/A	26.65%	-310.69%	36.58%	N/A

Latest ETON, EWTX, INDV, and DFTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ETON Eton Pharmaceuticals	$0.13	N/A	N/A	N/A	$27.11 million	N/A
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	N/A	N/A	N/A	N/A	N/A
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million
6/30/2026	Q2 2026	INDV Indivior	N/A	$5.75	N/A	$4.90	N/A	$343.00 million
5/14/2026	Q1 2026	ETON Eton Pharmaceuticals	$0.10	$0.05	-$0.05	$0.05	$22.31 million	$24.27 million
5/8/2026	Q1 2026	DFTX Definium Therapeutics	-$0.4780	-$0.71	-$0.2320	-$0.71	N/A	N/A
5/7/2026	Q1 2026	EWTX Edgewise Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DFTX Definium Therapeutics	0.15	4.69	4.69
ETON Eton Pharmaceuticals	0.62	1.21	0.88
EWTX Edgewise Therapeutics	N/A	22.61	22.61
INDV Indivior	N/A	0.86	0.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DFTX Definium Therapeutics	27.91%
ETON Eton Pharmaceuticals	27.86%
EWTX Edgewise Therapeutics	N/A
INDV Indivior	60.33%

Insider Ownership

Company	Insider Ownership
DFTX Definium Therapeutics	2.40%
ETON Eton Pharmaceuticals	16.49%
EWTX Edgewise Therapeutics	21.30%
INDV Indivior	0.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DFTX Definium Therapeutics	40	99.70 million	97.31 million	Optionable
ETON Eton Pharmaceuticals	20	27.39 million	22.88 million	Optionable
EWTX Edgewise Therapeutics	60	107.59 million	84.68 million	Optionable
INDV Indivior	1,051	121.92 million	121.02 million	Not Optionable

ETON, EWTX, INDV, and DFTX Headlines

Recent News About These Companies

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

August 4 at 1:21 PM | zacks.com

Supernus And Indivior Merger: There May Be Some Skepticism, But I Have Faith In This Deal

August 3 at 6:24 PM | seekingalpha.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)

August 3 at 3:15 PM | prnewswire.com

Indivior (NASDAQ:INDV) Stock Price Down 5.3% - What's Next?

August 3 at 1:59 PM | marketbeat.com

INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

August 3 at 10:44 AM | businesswire.com

Indivior Q2 Earnings Call Highlights

August 3 at 10:03 AM | marketbeat.com

Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates

August 3 at 8:46 AM | zacks.com

Supernus, Indivior merge to strengthen neuroscience drug portfolio

August 3 at 7:33 AM | reuters.com

Indivior (NASDAQ:INDV) Announces Earnings Results

August 3 at 7:10 AM | marketbeat.com

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

August 3 at 6:31 AM | globenewswire.com

Indivior (INDV) to Post Earnings on Tuesday

August 3 at 1:40 AM | americanbankingnews.com

Indivior PLC (NASDAQ:INDV) Given Average Recommendation of "Moderate Buy" by Brokerages

August 1, 2026 | marketbeat.com

This pharma stock eyes entry as opioid addiction specialist's profits surge 108%

July 31, 2026 | msn.com

Indivior to Report Second Quarter 2026 Financial Results and Host Webcast

July 23, 2026 | globenewswire.com

Indivior (INDV) Projected to Announce Quarterly Earnings on Thursday

July 23, 2026 | marketbeat.com

Billionaire Investor Howard Marks' Top 5 Holdings: A Buy at These Prices?

July 21, 2026 | 247wallst.com

Indivior (NASDAQ:INDV) Insider Christian Heidbreder Sells 18,586 Shares

July 14, 2026 | insidertrades.com

Indivior (NASDAQ:INDV) Insider Christian Heidbreder Sells 18,586 Shares of Stock

July 13, 2026 | marketbeat.com

Indivior Posts Strong Q1 Results, Raises 2026 Outlook

July 7, 2026 | theglobeandmail.com

Indivior Pharmaceuticals Inc. (INDV) is on the move, here's why the trend could be sustainable

June 29, 2026 | msn.com

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker

June 26, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ETON, EWTX, INDV, and DFTX Company Descriptions

Definium Therapeutics NASDAQ:DFTX

$42.32 +0.53 (+1.27%)

As of 08/4/2026 04:00 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Eton Pharmaceuticals NASDAQ:ETON

$45.83 +0.69 (+1.53%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$47.00 +1.17 (+2.55%)

As of 04:02 AM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Edgewise Therapeutics NASDAQ:EWTX

$44.71 +6.33 (+16.49%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$44.76 +0.05 (+0.12%)

As of 04:06 AM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Indivior NASDAQ:INDV

$36.50 -0.87 (-2.33%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$36.60 +0.09 (+0.26%)

As of 08/4/2026 07:54 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ETON, EWTX, INDV, and DFTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ETON, EWTX, INDV, and DFTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ETON, EWTX, INDV, and DFTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ETON, EWTX, INDV, and DFTX Company Descriptions

Definium Therapeutics NASDAQ:DFTX

Eton Pharmaceuticals NASDAQ:ETON

Edgewise Therapeutics NASDAQ:EWTX

Indivior NASDAQ:INDV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ETON, EWTX, INDV, and DFTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ETON, EWTX, INDV, and DFTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ETON, EWTX, INDV, and DFTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ETON, EWTX, INDV, and DFTX Company Descriptions

Definium Therapeutics NASDAQ:DFTX

Eton Pharmaceuticals NASDAQ:ETON

Edgewise Therapeutics NASDAQ:EWTX

Indivior NASDAQ:INDV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools